Regression of Advanced Hepatocellular Carcinoma with Lung Metastasis in Response to Sorafenib
Journal of Liver Cancer
; : 57-62, 2016.
Artigo
em Coreano
| WPRIM (Pacífico Ocidental)
| ID: wpr-194395
Biblioteca responsável:
WPRO
ABSTRACT
Sorafenib is a multi-targeted tyrosine kinase inhibitor that inhibits Raf kinase and the vascular endothelial growth factor receptor intracellular kinase pathway and is the first agent to demonstrate a statistically significant improvement in overall survival for patients with advanced hepatocellular carcinoma (HCC). However, there were few cases of partial or complete response reported in the previous studies. We herein report a case of dramatic partial response in a patient who had advanced HCC with multiple lung metastasis and portal vein thrombosis treated with sorafenib.
Texto completo:
Disponível
Base de dados:
WPRIM (Pacífico Ocidental)
Assunto principal:
Fosfotransferases
/
Proteínas Tirosina Quinases
/
Resultado do Tratamento
/
Carcinoma Hepatocelular
/
Trombose Venosa
/
Receptores de Fatores de Crescimento do Endotélio Vascular
/
Tratamento Farmacológico
/
Pulmão
/
Metástase Neoplásica
Limite:
Humanos
Idioma:
Coreano
Revista:
Journal of Liver Cancer
Ano de publicação:
2016
Tipo de documento:
Artigo